Biomarin Pharmaceutical

Quarterly Financials

Values in thousands 2025-06-30 2025-03-31 2024-12-31 2024-09-30
Revenue
$825,410
$745,145
$738,222
$745,740
Gross Profit
675,320
593,587
602,083
557,283
EBITDA
306,522
223,893
195,823
156,415
EBIT
295,189
235,226
172,216
137,409
Net Income
240,532
185,686
124,943
106,080
Net Change In Cash
825,410
745,145
738,222
745,740
Free Cash Flow
168,170
157,626
165,328
200,305
Cash
1,213,816
1,048,803
942,842
675,448
Basic Shares
196,643
196,474
196,581
197,147

Annual Financials

Values in thousands 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Revenue
$2,853,915
$2,419,226
$2,096,039
$1,846,275
Gross Profit
2,273,680
1,842,161
1,612,370
1,375,760
EBITDA
650,855
310,284
267,515
48,026
EBIT
554,429
205,898
165,546
-60,013
Net Income
426,859
167,645
141,561
-64,080
Net Change In Cash
2,853,915
2,419,226
2,096,039
1,846,275
Cost of Revenue
-61,882
Free Cash Flow
475,423
51,648
44,362
185,311
Cash
942,842
755,127
724,531
587,276
Basic Shares
196,708
191,595
188,963
182,852

Earnings Calls

Quarter EPS
2025-06-30
$1.44
2025-03-31
$1.13
2024-12-31
$0.92
2024-09-30
$0.55